Q-omics provides the consensus-scored RPS29P24 profile across patient tissues and cancer cell-line models. RPS29P24 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS29P24 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, RPS29P24 RNA expression shows 10,739 significant gene co-expression associations, with the highest sampling consensus in LUSC. Together, these results highlight KIRC, THCA, and LUSC as cancer lineages where RPS29P24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS29P24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS29P24 survival associations across molecular data types. RPS29P24 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS29P24 RNA expression–survival associations across cancer types. High RPS29P24 expression shows unfavorable associations in KIRC, ACC, PAAD, CESC and MESO, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS29P24 RNA expression.
This table summarizes RPS29P24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS29P24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS29P24 shows lower tumor expression in THCA. The THCA box plot shows higher RPS29P24 RNA expression in normal versus tumor tissue (log2 FC = −0.090, t-test p = .023).
This table shows molecular features associated with RPS29P24 in patient tissues and cancer cell lines. In patient samples, RPS29P24 shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set.
